Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

ANPD001

Cell therapy (Stem-cell derived) · Cell replacement · developed by Aspen Neuroscience

Phase 1 Most advanced trial
ASPE Developer
1 Registered trials

What is ANPD001?

ANPD001 is a cell therapy made from the patient's own skin cells reprogrammed into induced pluripotent stem cells, then differentiated into precursors of dopamine-producing brain cells. It is being studied in Parkinson disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (Stem-cell derived)
Mechanism
Cell replacement
Therapy area
Neurology
Developer
Aspen Neuroscience (ASPE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
H366LC5CFP

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06344026 Phase 1 Parkinson Disease Enrolling by invitation ASPE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Parkinson Disease

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the ASPE page.

Follow ASPE, the company behind ANPD001

See ASPE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ASPE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.